Open AccessAgomelatine and sertraline for the treatment of depression in type 2 diabetes mellitus
Author(s) -
Karaiskos D.,
Tzavellas E.,
Ilias I.,
Liappas I.,
Paparrigopoulos T.
Publication year - 2013
Publication title -
international journal of clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.756
H-Index - 98
eISSN - 1742-1241
pISSN - 1368-5031
DOI - 10.1111/ijcp.12112
Subject(s) - agomelatine , sertraline , medicine , depression (economics) , anxiety , diabetes mellitus , type 2 diabetes mellitus , placebo , antidepressant , type 2 diabetes , psychiatry , endocrinology , alternative medicine , pathology , economics , macroeconomics
Summary Objective The present study compared the efficacy of agomelatine and sertraline in the treatment of symptoms of depression/anxiety, diabetes self‐care and metabolic control in a sample of depressed patients with non‐optimally controlled type 2 diabetes mellitus ( DM ). Method This was an observational open label study of 40 depressed patients with DM who were randomly assigned to receive either agomelatine or sertraline, and were assessed over a 4‐month period for depression, anxiety, self‐care, fasting plasma glucose, haemoglobin A1c and body weight. Results Lower anxiety and depression scores as well as higher self‐care scores were measured in the agomelatine group compared with the sertraline group after 4 months of treatment. Although the main effects of treatment on final body weight and fasting plasma glucose were not significant, significantly lower final haemoglobin A1c levels were measured in the agomelatine group compared with the sertraline group. Both antidepressants were well tolerated and none of the patients dropped‐out of the study. Conclusion The main finding of the present small pilot study was that agomelatine may be a promising agent in the treatment of symptoms of depression and anxiety as well as in the improvement of health‐related behaviours, in depressed patients with type 2 DM possibly offering some advantages over sertraline. However, the lack of a placebo control group limits the generalisability of the findings and warrants further studies.